Population
Patients with end-stage pulmonary disorders undergoing lung transplantation
Design
Review
Authors
Loading...
Does not alter current BOS management; leaves open identification of effective pharmacological targets in lung transplant recipients.
This review highlights the complex pathogenesis of chronic lung allograft rejection and the need for better pharmacological targets to prevent or treat bronchiolitis obliterans syndrome.
Weigt et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: